Abstracts Archive - Page 1940 of 2607 - ACR Meeting Abstracts

Abstract Number: 1034 • 2015 ACR/ARHP Annual Meeting
Immunomodulation By a Second-Generation Peptidyl Arginine Deiminase Inhibitor Abrogates Collagen-Induced Arthritis in a Therapeutic Protocol
Anne-Marie Quirke¹, Joanna Kawalkowska², Fatemeh Ghari³, Venkataraman Subramaniam⁴, Paul Thompson⁵, Richard O. Williams¹, Nick La Thangue³ and Patrick J. Venables¹, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Kennedy Institute for Rheumatology, University of Oxford, Oxford, United Kingdom, ³Department of Oncology, University of Oxford, Oxford, United Kingdom, ⁴Biochemistry and Molecular Pharmacology, University of Massachusetts, Worcester, MA, ⁵University of Massachusetts, Worcester, MA
Background/Purpose: Citrullination is a post translational modification of arginine catalysed by peptidyl arginine deiminases (PADs) and may be important in generating pathogenic autoantibodies to citrullinated…
Abstract Number: 1035 • 2015 ACR/ARHP Annual Meeting
Synovium-Derived microRNAs Inhibit Bone Formation in Rheumatoid Arthritis
Ellen M. Gravallese¹, Yukiko Maeda², Nicholas H Farina³, Paul Fanning⁴ and Jane Lian³, ¹Lazare Research Bldg Ste 223, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, Worcester, MA, ³Department of Biochemistry, University of Vermont, Burlington, VT, ⁴Department of Orthopedics, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Articular bone erosion in rheumatoid arthritis (RA) is a consequence of synovial inflammation that leads to disability for patients. Cells within the synovium secrete…
Abstract Number: 1036 • 2015 ACR/ARHP Annual Meeting
Important Role of microRNA-146a in Inflammatory Arthritis By Controlling Local Bone Destruction
Victoria Saferding¹, Antonia Puchner², Eliana Goncalves-Alves³, Melanie Hofmann³, Emine Sahin⁴, Silvia Hayer⁵, Philippe Georgel⁶, Marije M. Koenders⁷, Gernot Schabbauer⁴, Josef S. Smolen³, Guenter Steiner⁸, Kurt Redlich³ and Stephan Blüml³, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Vascular Biology and Thrombosis research, Medical University Vienna, Vienna, Austria, ⁵Waehringer Guertel 18-20 A-A09, Medical University of Vienna, Vienna, Austria, ⁶Centre de Recherche en Immunologie et Hématologie, Université de Strasbourg, Strasbourg, France, ⁷Medical Center, Radboud University Nijmegen, Nijmegen, Netherlands, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: MicroRNA (MiR-) 146a is a key regulator of the innate immune response and has also been shown to suppress cancer development in myeloid cells.…
Abstract Number: 1037 • 2015 ACR/ARHP Annual Meeting
Impaired Regulatory T Cell Survival in the Pathogenesis of Autoreactive Arthritis Mediated By CD11c-Deletion of Flip
Qi Quan Huang¹, Renee E. Doyle¹, Robert Birkett², Deyu Fang³, Syamal K. Datta¹ and Richard M. Pope¹, ¹Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Division of Rheumatology, Department od Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: We have generated a mouse line with Flip conditionally deleted in CD11c-cre expressing cells (CD11c-Flip-KO, named HUPO), which spontaneously develops erosive arthritis resembling rheumatoid…
Abstract Number: 1038 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha and Peptidylarginine Deiminase 4 in Lung and Joint Inflammation
Mandar Bawadekar¹, Annette Gendron-Fitzpatrick², Thomas F. Warner³, Lennart K.A. Lundblad⁴, Paul Thompson⁵ and Miriam A. Shelef^1,6, ¹Medicine, University of Wisconsin, Madison, WI, ²Comparative Pathology Laboratory of the Research Animal Resources Center and Pathobiological Sciences, University of Wisconsin, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, ⁴Medicine, The University of Vermont, Burlington, VT, ⁵University of Massachusetts, Worcester, MA, ⁶Medicine, William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The relationship between lung and joint inflammation in rheumatoid arthritis is poorly understood. About 10% of people with rheumatoid arthritis develop interstitial lung disease…
Abstract Number: 1039 • 2015 ACR/ARHP Annual Meeting
The Safety and Effect on Disease Activity of Tocilizumab in Combination with MTX Versus Tocilizumab Monotherapy in Patients with Mild to Moderate RA: An Attempt to Optimise the Treatment Response
Burkhard Leeb^1,2, Raimund Lunzer³, Peter Fasching⁴, Manfred Herold⁵, O. Zamani⁶, Winfried Graninger⁷ and OPTIMISE trial Investigators, ¹2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria, ²Department of Clinical Rheumatology, Karl Landsteiner Society, Stockerau, Austria, ³Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁴Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ⁵Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ⁶Rheumazentrum Favoriten, Wien, Austria, ⁷Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Background/Purpose: An Austrian multi-center study of the effect on disease activity and the safety of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus TCZ Monotherapy…
Abstract Number: 1040 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Long Term Rituximab Use in Rheumatoid Arthritis – Results from the British Society of Rheumatology Biologics Register
Alexander G.S. Oldroyd¹, Deborah P.M. Symmons¹, Lianne Kearsley-Fleet¹, Kath Watson¹, Mark Lunt², Jamie Sergeant¹, Kimme L. Hyrich¹ and on behalf of the BSRBR-RA, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Analysis of long term continuation of biologics in rheumatoid arthritis (RA) is considered a valid surrogate for treatment effectiveness and safety. Only a small…
Abstract Number: 1041 • 2015 ACR/ARHP Annual Meeting
Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, George A. Tomlinson⁴, Deborah Marshall⁵, Daniel Devoe⁵ and Claire Bombardier⁶, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare methotrexate based disease-modifying anti-rheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naïve to or after an inadequate response (IR) to methotrexate. …
Abstract Number: 1042 • 2015 ACR/ARHP Annual Meeting
Pragmatic Multicenter Open-Label Randomized Controlled Trial of Stopping TNF-Inhibitors in Rheumatoid Arthritis Patients in Remission or Stable Low Disease Activity in the Netherlands
Marjan Ghiti Moghadam¹, Harald E. Vonkeman², Peter M. ten Klooster³, Janneke Tekstra⁴, Dirkjan van Schaardenburg⁵, Mirian Starmans-kool^6,7, Elisabeth Brouwer⁸, Reinhard Bos⁹, Willem F. Lems¹⁰, Edgar Colin¹¹, Cornelia F. Allaart¹², Inger L. Meek¹³, Robert B.M. Landewé¹⁴, Hein J. Bernelot Moens¹⁵, Piet van Riel¹³, Mart A.F.J. van de Laar¹⁶, Tim Jansen¹⁷ and on behalf of the Dutch National POET Collaboration., ¹rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Jan van Breemen Research Institute, Amsterdam, Netherlands, ⁶Rheumatology, Orbis Medical Center, Geleen-Sittard, Netherlands, ⁷Rheumatology, Atrium Medical center, Heerlen, Netherlands, ⁸Rheumatology, University Medical center Groningen, Groningen, Netherlands, ⁹Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ¹⁰Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ¹¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ¹²Department of Rheumatology, Leiden Universitary Medical Center, Leiden, Netherlands, ¹³Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹⁵rheumatology, Ziekenhuisgroep Twente, Almelo, Netherlands, ¹⁶Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ¹⁷VieCuri Medical Center, Venlo, Netherlands
Background/Purpose: TNF-inhibitors (TNFi) are effective treatments of rheumatoid arthritis (RA). It is not clear if patients in remission or stable low disease activity need to…
Abstract Number: 1043 • 2015 ACR/ARHP Annual Meeting
Enhancing Comparative Effectiveness Research By Combining Observational and Randomized Trial Data to Personalize the Choice Between Methotrexate and Triple Therapy for Methotrexate-Naïve Patients with Early Rheumatoid Arthritis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, Gilles Boire⁴, Carol Hitchon⁵, Edward C. Keystone⁶, Boulos Haraoui⁷, J Carter Thorne⁸, Diane Tin⁹, Janet E. Pope¹⁰, Daming Lin¹¹, VP Bykerk¹² and CATCH investigators, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Institut de Rhumatologie, Montreal, QC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Randomized controlled trials (RCTs) are considered the gold standard for comparing efficacy of treatments, but the results may be less generalizable to clinical practice…
Abstract Number: 1044 • 2015 ACR/ARHP Annual Meeting
Many Patients with Early Rheumatoid Arthritis Want Triple Therapy: An Analysis Combining Comparative Effectiveness Research and Patients Preferences to Inform Treatment Recommendations
Glen S. Hazlewood^1,2, Claire Bombardier³, George A. Tomlinson⁴ and Deborah Marshall⁵, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Medicine, University Health Network, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada
Background/Purpose: Growing evidence supports the efficacy of triple therapy (methotrexate + sulphasalazine + hydroxychloroquine) for controlling disease activity in patients with early rheumatoid arthritis (ERA),…
Abstract Number: 1045 • 2015 ACR/ARHP Annual Meeting
Baricitinib, Methotrexate, or Baricitinib Plus Methotrexate in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Phase 3 Trial Results
Roy Fleischmann¹, Tsutomu Takeuchi², Douglas E. Schlichting³, William L. Macias³, Terence Rooney³, Sirel Gurbuz³, Ivaylo Stoykov³, Scott D. Beattie³, Wen-Ling Kuo³ and M Schiff⁴, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²Keio University School of Medicine, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Colorado, Denver, CO
Background/Purpose: In 2 completed phase 3 studies, baricitinib (bari) improved disease activity with a satisfactory safety profile in patients (pts) with moderately-to-severely active RA who…
Abstract Number: 1046 • 2015 ACR/ARHP Annual Meeting
Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors
Mark C. Genovese¹, Joel M. Kremer², Cynthia Kartman³, Douglas E. Schlichting³, Li Xie³, Tara Carmack⁴, William L. Macias³ and Josef S. Smolen⁵, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany, NY, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Durham, NC, ⁵Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib, an oral inhibitor of JAK1/JAK2, improved disease activity with an acceptable safety profile in a phase 3 study (RA-BEACON) of patients with active…
Abstract Number: 1047 • 2015 ACR/ARHP Annual Meeting
Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in Two Phase 3 Studies
Paul Emery¹, Iain McInnes², Mark C. Genovese³, Josef S. Smolen⁴, Joel Kremer⁵, Maxime Dougados⁶, Douglas E. Schlichting⁷, Terence Rooney⁷, Maher Issa⁷, Stephanie de Bono⁷, William L. Macias⁷, Veronica Rogai⁷, Steven H. Zuckerman⁷ and Peter C. Taylor⁸, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ²Glasgow Biomedical Research Centre, Glasgow, United Kingdom, ³Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Albany Medical College, Albany, NY, ⁶Paris-Descartes University, Paris, France, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom
Background/Purpose: Baricitinib (bari) is an oral, reversible inhibitor of Janus kinase (JAK)1/JAK2 being developed as QD treatment for patients (pts) with RA. In phase (ph)…
Abstract Number: 1048 • 2015 ACR/ARHP Annual Meeting
Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
R Westhovens¹, Rieke Alten², Dace Pavlova³, Favio Enríquez-Sosa⁴, Minodora Mazur⁵, Maria Greenwald⁶, Annegret Van der Aa⁷, Frédéric Vanhoutte⁷, Chantal Tasset⁷ and Pille Harrison⁷, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, ²Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³LTD M & M Centrs, Carnikava, Latvia, ⁴CLINSTILE, S.A. DE C.V, Mexico, Mexico, ⁵IMSP Institul de Cardiologie, Chisinau, Moldova, ⁶Desert Medical Advances, Palm Desert, CA, ⁷Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].